Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Update

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw a significant decline in short interest in the month of October. As of October 15th, there was short interest totaling 3,000 shares, a decline of 82.7% from the September 30th total of 17,300 shares. Based on an average daily trading volume, of 8,700 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.0% of the company’s shares are sold short. Currently, 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 8,700 shares, the days-to-cover ratio is currently 0.3 days.

Ascentage Pharma Group International Stock Down 0.3%

AAPG opened at $33.40 on Thursday. The company has a 50 day moving average of $38.76 and a two-hundred day moving average of $34.76. The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 1.31. Ascentage Pharma Group International has a 52-week low of $16.50 and a 52-week high of $48.45.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in AAPG. Chevy Chase Trust Holdings LLC acquired a new stake in shares of Ascentage Pharma Group International during the second quarter worth $227,000. Tema Etfs LLC bought a new position in Ascentage Pharma Group International in the 2nd quarter valued at about $610,000. Hsbc Holdings PLC bought a new position in Ascentage Pharma Group International in the 2nd quarter valued at about $391,000. Finally, Monashee Investment Management LLC bought a new position in Ascentage Pharma Group International in the 1st quarter valued at about $3,511,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.